• TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine
    Nov 20 2026
    SHOW NOTES
    - Dear TSC Alliance Leadership and Natural History Database Steering Committee,.pdf
    - TSC Alliance contact: biosample@tscalliance.org
    - Host contact: Jill Woodworth (pjlacy6@gmail.com)
    - MA AG consumer complaint form: mass.gov/how-to/file-a-consumer-complaint
    - Apertura Gene Therapy press release (May 2026)
    - TSC Alliance NHD page: tscalliance.org
    - Van Andel Institute Biorepository: Grand Rapids, MI
    - Key terms: AAV, TSC1, TSC2, vector sizing, DRG toxicity, antibody neutralization, 15-year FDA follow-up mandate
    ---
    KEY DEFINITIONS
    *AAV Capsid Delivery Platform: An adeno-associated virus (AAV) vector system engineered to deliver functional genetic material into host cells. In this context, it utilizes a viral shell (capsid) to cross specific biological barriers and target neural tissues. Key operational constraints and clinical considerations include:
    *Packaging Limits: AAV vectors have a strict genetic payload capacity of approximately 4.7 kilobases total (including ITRs), leaving roughly 4.4 kilobases for the transgene cassette. Genes exceeding this length (such as full-length TSC2, at ~4.3 kb coding sequence plus necessary promoter and polyA signals) present significant packaging challenges.
    *Immune Response & Irreversibility:** Exposure to an AAV capsid triggers neutralizing antibody production by the patient's immune system, permanently barring subsequent administration of AAV-based treatments.
    *Monitoring Requirements: Regulatory standards (such as FDA mandates) require extended long-term follow-up monitoring—typically lasting up to 15 years—to evaluate long-term safety, potential hepatotoxicity, and dorsal root ganglion (DRG) toxicity.
    I discuss the TSC gene therapy agreement and the TSC Natural History Database (NHD), raising questions about consent, data governance, and long-term impacts on families. I explains the NHD’s scope (running since 2006 with 2,700+ participants, clinical histories and biosamples stored at Van Andel Institute, and thousands of samples distributed to researchers) and critiques the May 2026 TSC Alliance partnership with for-profit Apertura Gene Therapy, backed by Deerfield Management, to develop an AAV gene replacement therapy delivering TSC1/TSC2 to the brain. I outline concerns about lack of reconsent when minors become adults, unclear withdrawal processes, financial protections for participants, and under-communicated risks of AAV therapies (high cost, permanent antibody barrier to future AAV dosing, 15-year monitoring, and TSC2 packaging constraints). I describe a certified letter demanding written answers and offers steps for parents to request consent forms, ask about withdrawal, and file complaints if needed.

    00:00 Intro and Big Questions
    01:57 What We Signed
    02:34 Inside the NHD Database
    03:47 Apertura Partnership Explained
    04:59 Consent and Governance Gaps
    06:30 Gene Therapy Risks Breakdown
    09:29 My Certified Letter
    09:37 Five Demands for Transparency
    12:35 What You Can Do Now
    14:48 Final Thoughts and Wrap Up
    https://aperturagtx.com/news/apertura-gene-therapy-and-the-tsc-alliance-announce-collaboration-to-advance-gene-therapy-programs-designed-to-treat-tuberous-sclerosis-complex-tsc/
    https://www.prnewswire.com/news-releases/apertura-gene-therapy-showcases-the-progress-of-its-novel-human-transferrin-receptor-aav-capsid-tfr1-capx-and-preclinical-programs-for-tuberous-sclerosis-complex-tsc-at-the-american-society-of-gene-and-cell-therapy-asgct-ann-302448607.html
    https://www.prnewswire.com/news-releases/tsc-alliance-and-apertura-gene-therapy-complete-preclinical-pilot-study-evaluating-aav-gene-therapy-approach-designed-for-tsc1-302838523.html

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    16 mins
  • TSC Talks 3.0 (not) Research ~ In the Stone Chamber
    May 6 2026
    Taking a break from the harsh closed loops and hunkering down in dis stone chamber to give a little freestyle riff for this episode from the stone chamber
    no links
    except go watch the video. the audio just won't cut it on this one
    https://youtu.be/bEIqg2lcDU0

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    3 mins
  • TSC Talks 3.0 Research~Episode 10
    Apr 29 2026
    I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.

    Source Links for Further Research
    I. Rare Disease Advocacy and Funding (Conflicts of Interest)
    [TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)
    [TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)
    [TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)
    [TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)
    [NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)
    [NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/)
    [EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)
    [Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)
    [NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)
    II. Gene Therapy (CRISPR), Risks, and Regulation
    [FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)
    [CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)
    [CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)
    [FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)
    III. Vaccines, Toxins, and Environmental Amplification
    [TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)
    [Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/)
    [Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)
    [Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)
    IV. Alternative and Holistic Approaches
    [Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-\(mtor\)-pathway)
    [Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)
    [Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)
    [Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)
    contact Jill: pjlacy6@gmail.com

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    36 mins
  • TSC Talks 3.0 Research~Episode 9
    Apr 22 2026
    In this episode, I get into mitigation strategies related to the increasing reliance on tech with the arrival of 6G particularly for those living with a chronic and or rare disease that is on multiple medications and dependent on the grid. What would be considered alternative or holistic therapies such as grounding, sound therapy, ketogenic diet and exercise have all been proven to help support the full field in finding homeostasis even with a condition such as TSC and can improve overall health and quality of life as a support beyond meds and other more drastic regimens. I also talk about the similarities between CPTSD and TAND (TSC Associated Neuropsychiatric Disorder) and the importance of understanding the "energetics" of a rare disease when advocating for one's self and/or loved ones. The system will add additional labels and complicate understanding. I hope to explore further the CPTSD connection as I feel it as AS relevant as the limited focus of TAND.

    Full list of links: https://docs.google.com/document/d/e/2PACX-1vQv_yBMqtFvxQmhm31TXozv20_nEGxCTwjUCclYrEK2yE9NGR6rQqc1GyMsA76lUNtNrZda-FF_Z2IM/pub


    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    36 mins
  • TSC Talks 3.0 Research~Episode 8
    Apr 15 2026
    Episode 8 of TSC Talks 3.0 Research... continuing on with the extensive history of the rare disease Tuberous Sclerosis Complex, the set up for data harvesting and gene editing and the inevitability of enhanced grid adhesion. Woohoo! Next episode I'm gonna go into mitigation and the upswing of the sitch. Links:mindandbodyexercises.comhttps://medium.comhttps://maescenter.comrockarch.orgtikvahhealthandwellness.comnih.govnih.govnutritiondiagnostics.com.aunih.govpsychologytoday.comnih.govmcgill.cachop.eduhttps://historyofvaccines.orgnih.govjpeds.comhttps://time.comnih.govnih.govnih.gov2minutemedicine.comnih.govnih.govsciencedirect.comnih.govcdc.govnih.govhttps://richd.orgnih.govwikipedia.orgempr.comhttps://historyofvaccines.orghttps://drgreenmom.commayoclinic.orgkaiserpermanente.orgnih.govkff.orgforbes.comitu.intciocoverage.comhttps://studyfinds.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    30 mins
  • TSC Talks 3.0 Research~Episode 7
    Apr 8 2026
    The history of Tuberous Sclerosis Complex.
    they're juicing it.
    Some queries related to the complexity of epigenetic variables and the overlords decision to focus on genetics only for the sake of "simplicity"...
    Just my opinion?
    I welcome all listeners and critical thinkers.
    📚 Primary Research & Databases PubMed Central (Full-Text Archive): https://pmc.ncbi.nlm.nih.gov
    PubMed (Citations & Abstracts): https://pubmed.ncbi.nlm.nih.gov
    ScienceDirect: sciencedirect.com
    Wiley Online Library: https://onlinelibrary.wiley.com
    Springer Link: https://link.springer.com
    ResearchGate: researchgate.net Academia.edu: academia.edu
    🏥 Health Organizations & Agencies NIH / National Library of Medicine: https://www.ncbi.nlm.nih.gov
    NINDS (Neurological Disorders): https://www.ninds.nih.gov
    MedlinePlus: https://medlineplus.gov
    HRSA (Health Resources): hrsa.gov
    Texas Children’s Hospital: texaschildrens.org
    TSC Alliance: tscalliance.org
    Epilepsy Foundation: epilepsy.com
    🔬 Specialized Medical Journals
    The Lancet: thelancet.com Pediatric Neurology: pedneur.com
    Neurotherapeutics: neurotherapeuticsjournal.org
    Frontiers in Science: frontiersin.org eLife Sciences: https://elifesciences.org
    AMA Journal of Ethics: ama-assn.org
    AAP Publications: aap.org ACR Journals: https://acrjournals.onlinelibrary.wiley.com
    ACR Abstracts: https://acrabstracts.org
    2 Minute Medicine: https://www.2minutemedicine.com
    📰 News, Legal & Historical Context
    TIME Magazine: https://time.com
    Medical Xpress: https://medicalxpress.com
    History of Vaccines: https://historyofvaccines.org
    Texas Vaccine Lawyers: texasvaccinelawyers.com
    Digital Commons (Rockefeller): rockefeller.edu HealthCentral: healthcentral.com Changing Aging: https://changingaging.org
    Medium: https://medium.com
    Meridian Health Clinic: https://meridianhealthclinic.com
    Wikipedia: wikipedia.org WikiDoc: wikidoc.org
    contact Jill ~ pjlacy6@gmail.com

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    34 mins
  • TSC Talks 3.0 Research~Episode 6
    Apr 1 2026
    In Episode 6 of TSC Talks Research 3.0, I finish up the discussion of CRISPR and TSC and the trajectory, I get into cannabis and the way they've deglimmered exploration of consciousness for those with rare diseases on hefty meds and how this relates to the cultivated biosphere that limits the full potential of the divine human. So many the templates for data and experimentation to build the current Healthcare 4.0 system and Precision Medicine. While many will be helped, there will be a dependence on the grid system.
    YouTube Video: https://youtu.be/OqLKIZ7Q54s?si=8svWmKHp4ekiFOnR
    Links: https://www.liebertpub.com/doi/10.1089/crispr.2024.0079
    https://pubmed.ncbi.nlm.nih.gov/39654514/
    https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7793581/
    https://innovativegenomics.org/news/crispr-clinical-trials-2026/ https://frontlinegenomics.com/sickle-cell-disease-a-2024-update/ epidiolexhcp.com
    nih.gov
    sciencedaily.com
    https://www.researchgate.net/publication/348347376_Gene_therapy_for_tuberous_sclerosis_complex_type_2_in_a_mouse_model_by_delivery_of_AAV9_encoding_a_condensed_form_of_tuberin globalgenes.org neurologylive.com berkeley.edu ccf.org

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    32 mins
  • TSC Talks 3.0 Research~Episode 5
    Mar 25 2026
    In this episode I share information on the risks and side effects of CRISPR for individuals with TSC and in general as well as go into how those affected with TSC are "test bunnies" for much of this new technology, and my theories with documentation of why this is happening. I also go over some of the "no touch" technologies being rolled out and tested on those with diseases such as TSC where the nature of the genetics, a "monogenic" disorder, makes it a more suitable population to experiment on to gain information than other more common disorders, such as Alzheimer's, which involve 100s of genetic factors. TSC population is kept in that "test bunny" role without ever addressing the external factors that make the disease more difficult to manage in the first place.LINKS:pmc.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://cdmrp.health.mil/tscrp/defaulthttp://tuberous-sclerosis.org/research/tsa-funded-research/https://www.mdpi.com/2075-1729/15/3/368https://www.tscalliance.org/wp-content/uploads/2023/02/Training-Packet-Documents.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3010088/https://pmc.ncbi.nlm.nih.gov/articles/PMC4527140/https://pubmed.ncbi.nlm.nih.gov/19028034/https://pmc.ncbi.nlm.nih.gov/articles/PMC6851053/https://www.youtube.com/watch?v=hXRRq-dFuYghttps://www.youtube.com/watch?v=Hu2TvhhdEHYhttps://www.youtube.com/watch?v=BFuXttZspaYhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5727703/https://globalgenes.org/raredaily/transforming-tsc-epilepsy-with-a-precision-therapy/https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/https://pmc.ncbi.nlm.nih.gov/articles/PMC3164024/https://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/https://www.biorxiv.org/content/10.1101/2024.02.22.581652v1.full-texthttps://pmc.ncbi.nlm.nih.gov/articles/PMC6408922/https://www.mdpi.com/2076-3417/14/3/1132https://pmc.ncbi.nlm.nih.gov/articles/PMC3744999/https://www.researchgate.net/publication/24217930_Magnetically_Responsive_Nanoparticles_for_Drug_Delivery_Applications_Using_Low_Magnetic_Field_Strengthshttps://pmc.ncbi.nlm.nih.gov/articles/PMC2933363/https://pmc.ncbi.nlm.nih.gov/articles/PMC7998448/https://pmc.ncbi.nlm.nih.gov/articles/PMC9230665/Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    29 mins